Aeterna Zentaris: Rises on strategic review plans

COSCIENS Biopharma

12/03/2019 22:25

** U.S.-listed shares of Canadian drug developer  AEZS.N  up
6.5 pct at $3.93 after the bell     
    ** Aeterna hires investment bank Company of Torreya to
review strategic options, including sale of the company
 urn:newsml:reuters.com:*:nGNX9sSm5H
    ** Potential transactions include opportunities to license
macimorelin, AEZS' product for the diagnosis of adult growth
hormone deficiency, outside of U.S. and Canada
    ** Co says there is no defined timeline for the review
    ** Company has a market cap of about $61 mln

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208; Reuters Messaging:
tamara.mathias.thomsonreuters.com@reuters.net))